Oscient reiterated by JMP at strong buy

Oscient Therapeutics Inc. was reiterated by JMP Securities analyst Adam Cutler at a strong buy rating with a price target on the stock of $6 per share following weekly prescription data on its pneumonia and chronic bronchitis drug Factive and testosterone gel Testim. Oscient shares Monday were down $0.04, or 1.50%, at $2.62 on volume of 770,331 shares versus the three-month running average of 636,702 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.